ANDA 202917, held by Sun Pharm. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 202917 (Metformin Hydrochloride), held by Sun Pharm, was first approved by FDA on Aug 1, 2016, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 1, 2016 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride1GM · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Sep 27, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jan 3, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 3, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 22, 2019 | Supplement 7Manufacturing | Approved | None posted |
| Aug 1, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters